Drugs / NTA-476
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06520449 | Sep → Dec 2024 | prostate cancer | Melbourne Theranostic Innovation Centre | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTA-476 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06520449 ↗ |
| Known as | 68Ga-NTA-476 | “This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476.” NCT06520449 ↗ |
| Modality | Peptide | “small peptide targeting moiety” NCT06520449 ↗ |
| Route | Intravenous | “intravenous bolus injection” NCT06520449 ↗ |